Dalkeith, United Kingdom

Laura En Allan

This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignee: Trevena, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Laura En Allan. Retrieved from https://idiyas.com/inventor/laura-en-allan

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 1 

% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Laura En Allan and Her Patent on δ-Opioid Modulators.

Introduction

Laura En Allan is an inventor associated with Dalkeith, Great Britain, and Trevena, Inc. Her patent work concerns pharmaceutical compounds and their solid-state forms.

Latest Patents

Allan is named on 1 patent, titled “Crystalline and Amorphous Forms of a δ-Opioid Modulator.” The disclosure describes novel crystalline forms of a compound that acts as a δ-opioid effector, methods for preparing and precipitating its amorphous and crystalline forms, and potential uses for those forms.

Career Highlights

The patent reflects work on the preparation and characterization of pharmaceutical compound forms. Such research can support the development of drug candidates and methods for producing them.

Collaborations

Allan’s listed coworkers include Patrick J. Koestler and Hayley A. Reece. Their shared patent work connects their names with research into δ-opioid modulators and their crystalline and amorphous forms.

Conclusion

Laura En Allan’s patent contribution focuses on pharmaceutical forms of a δ-opioid modulator and related preparation methods, highlighting her connection to drug research at Trevena, Inc.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…